Tonix Pharmaceuticals is planning the launch of a Phase 2 clinical trial to test its TNX-2900 nasal spray — containing a specialized form of oxytocin — in children and teens with Prader-Willi syndrome (PWS). The company has already received clearance from the U.S. Food and Drug Administration (FDA) to…
Read more
A Phase 3 clinical trial testing ACP-101 for hyperphagia, or uncontrollable hunger, in Prader-Willi syndrome (PWS) patients failed to meet its primary and secondary goals. Top-line results from the trial of Acadia Pharmaceuticals’ experimental nasal spray, dubbed COMPASS PWS (NCT06173531), showed no significant differences between the ACP-101…
“Hyperphagia,” or the extreme drive to consume food, is a sizable word that is difficult for me to pronounce. It is a symptom of Prader-Willi syndrome (PWS), which my adult son, Robert, has. In people with PWS, the hypothalamus, a brain structure that regulates several bodily functions, including…
Prader-Will syndrome is a rare and complex genetic condition that results in a variety of physical and mental symptoms. Learn more about the disease here.
Prader-Willi is caused by genetic changes in a particular area of chromosome 15. Learn more about what causes the disease here.
Symptoms of Prader-Willi range from physical impairments to cognitive and behavioral issues. Learn more about the symptoms of the disease here.
Get regular updates to your inbox.
